Clinical outcomes of rare hepatocellular carcinoma variants compared to pure hepatocellular carcinoma

References

• Organization, W. H. Cancer; 2018 Available from: http://www.who.int/news-room/fact-sheets/detail/cancer. Accessed 629, 2019
   Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30. doi:10.3322/caac.2144229313949
   PubMed Web of Science ®Google Scholar
• Altekruse SF, Henley SJ, Cucinelli JE, McGlynn KA. Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol. 2014;109:542–553. doi:10.1038/ajg.2014.1124513805
   PubMed Web of Science ®Google Scholar
• Khalaf N, Ying J, Mittal S, et al. Natural history of untreated hepatocellular carcinoma in a US cohort and the role of cancer surveillance. Clin Gastroenterol Hepatol. 2017;15:273–281.e271. doi:10.1016/j.cgh.2016.07.03327521507
   PubMed Web of Science ®Google Scholar
• Jernigan PL, Wima K, Hanseman DJ, et al. Natural history and treatment trends in hepatocellular carcinoma subtypes: insights from a national cancer registry. J Surg Oncol. 2015;112:872–876. doi:10.1002/jso.2408326603598
   PubMed Web of Science ®Google Scholar
• Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet (London, England). 2012;379:1245–1255. doi:10.1016/s0140-6736(11)61347-0
   PubMed Web of Science ®Google Scholar
• Lesurtel M, Clavien PA. 2010 international consensus conference on liver transplantation for hepatocellular carcinoma: texts of experts. Liver Transpl. 2011;17(Suppl 2):S1–S5. doi:10.1002/lt.22350
   Web of Science ®Google Scholar
• Llovet JM, Link E, Parish S, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390. doi:10.1056/NEJMoa070885718650514
   PubMed Web of Science ®Google Scholar
• Kudo, M., Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet (London, England). 2018;391:1163–1173. doi:10.1016/s0140-6736(18)30207-1
   PubMed Web of Science ®Google Scholar
• Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England). 2017;389:56–66. doi:10.1016/s0140-6736(16)32453-9
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet (London, England). 2017;389:2492–2502. doi:10.1016/s0140-6736(17)31046-2
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379:54–63. doi:10.1056/NEJMoa171700229972759
   PubMed Web of Science ®Google Scholar
• Zhu, AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19:940–952. doi:10.1016/s1470-2045(18)30351-629875066
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Davila JA. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology. 2004;39(3):798–803. doi:10.1002/hep.2009614999699
   PubMed Web of Science ®Google Scholar
• Stipa, F., Yoon SS, Liau KH, et al. Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer. 2006;106:1331–1338. doi:10.1002/cncr.2170316475212
   PubMed Web of Science ®Google Scholar
• Kassahun WT. Contemporary management of fibrolamellar hepatocellular carcinoma: diagnosis, treatment, outcome, prognostic factors, and recent developments. World J Surg Oncol. 2016;14(151). doi:10.1186/s12957-016-0903-8
   Web of Science ®Google Scholar
• Ang CS, Kelley RK, Choti MA, et al. Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium. Gastrointest Cancer Res. 2013;6:3–9.23505572
   PubMedGoogle Scholar
• Mayo SC, Mavros MN, Nathan H, et al. Treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma: a national perspective. J Am Coll Surg. 2014;218:196–205. doi:10.1016/j.jamcollsurg.2013.10.01124315886
   PubMed Web of Science ®Google Scholar
• Kim YJ, Rhee H, Yoo JE, et al. Tumour epithelial and stromal characteristics of hepatocellular carcinomas with abundant fibrous stroma: fibrolamellar versus scirrhous hepatocellular carcinoma. Histopathology. 2017;71:217–226. doi:10.1111/his.1321928326574
   PubMed Web of Science ®Google Scholar
• Sakhuja, P., Mishra PK, Rajesh R, et al. Clear cell hepatocellular carcinoma: back to the basics for diagnosis. J Cancer Res Ther. 2015;11(656). doi:10.4103/0973-1482.136041
   Web of Science ®Google Scholar
• Liu Y, Nickleach D, Zhang C, Switchenko J, Kowalski J. Carry out streamlined routine data analyses with reports for observational studies: introduction to a series of generic SAS ® Macros. Version 2. F1000Res. 2018;7:1955. doi:10.12688/f1000research.16866.2
   Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7-30. doi: doi:10.3322/caac.21442
   Google Scholar
• Craig JR, Peters RL, Edmondson HA, Omata M. Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features. Cancer. 1980;46:372–379. doi:10.1002/1097-0142(19800715)46:2<372::aid-cncr2820460227>3.0.co;2-s6248194
   PubMed Web of Science ®Google Scholar
• Eggert T, McGlynn KA, Duffy A, Manns MP, Greten TF, Altekruse SF. Fibrolamellar hepatocellular carcinoma in the USA, 2000-2010: a detailed report on frequency, treatment and outcome based on the surveillance, epidemiology, and end results database. United European Gastroenterol J. 2013;1:351–357. doi:10.1177/2050640613501507
   PubMed Web of Science ®Google Scholar
• Sugiki T, Yamamoto M, Taka K, Nakano M. Specific characteristics of scirrhous hepatocellular carcinoma. Hepato-gastroenterology. 2009;56:1086–1089.19760947
   PubMedGoogle Scholar
• Lee JH, Choi MS, Gwak GY, et al. Clinicopathologic characteristics and long-term prognosis of scirrhous hepatocellular carcinoma. Dig Dis Sci. 2012;57:1698–1707. doi:10.1007/s10620-012-2075-x22327241
   PubMed Web of Science ®Google Scholar
• Maeda T, Adachi E, Kajiyama K, Takenaka K, Sugimachi K, Tsuneyoshi M. Spindle cell hepatocellular carcinoma. A clinicopathologic and immunohistochemical analysis of 15 cases. Cancer. 1996;77:51–57. doi:10.1002/(sici)1097-0142(19960101)77:1<51::Aid-cncr10>3.0.Co;2-78630939
   PubMed Web of Science ®Google Scholar
• Sapisochin G, Fidelman N, Roberts JP, Yao FY. Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma. Liver Transpl. 2011;17:934–942. doi:10.1002/lt.2230721438129
   PubMed Web of Science ®Google Scholar
• Jarnagin WR, Weber S, Tickoo SK, et al. Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer. 2002;94:2040–2046. doi:10.1002/cncr.1039211932907
   PubMed Web of Science ®Google Scholar
• Ringe B, Wittekind C, Weimann A, Tusch G, Pichlmayr R. Results of hepatic resection and transplantation for fibrolamellar carcinoma. Surg Gynecol Obstet. 1992;175:299–305.1329242
   PubMedGoogle Scholar
• Pinna AD, Iwatsuki S, Lee RG, et al. Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation. Hepatology. 1997;26:877–883. doi:10.1002/hep.5102604129328308
   PubMed Web of Science ®Google Scholar
• Kaseb AO, Shama M, Sahin IH, et al. Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma. Oncology. 2013;85:197–203. doi:10.1159/00035469824051705
   PubMed Web of Science ®Google Scholar
• Mavros MN, Mayo SC, Hyder O, Pawlik TM. A systematic review: treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma. J Am Coll Surg. 2012;215(6):820–830. doi:10.1016/j.jamcollsurg.2012.08.00122981432
   PubMed Web of Science ®Google Scholar
• Wood WJ, Rawlings M, Evans H, Lim CN. Hepatocellular carcinoma: importance of histologic classification as a prognostic factor. Am J Surg. 1988;155:663–666. doi:10.1016/s0002-9610(88)80139-92835911
   PubMed Web of Science ®Google Scholar
• Edmondson HA. Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood. AMA J Dis Child. 1956;91:168–186.13282629
   PubMedGoogle Scholar
• El-Gazzaz G, Wong W, El-Hadary MK, et al. Outcome of liver resection and transplantation for fibrolamellar hepatocellular carcinoma. Transpl Int. 2000;13(Suppl 1):S406–S409.11112043
   PubMedGoogle Scholar
• Schlitt HJ, Neipp M, Weimann A, et al. Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J Clin Oncol. 1999;17:324–331. doi:10.1200/jco.1999.17.1.32410458250
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhang G, Wu J, Jia M. Adjuvant therapy for hepatocellular carcinoma: current situation and prospect. Drug Discov Ther. 2013;7:137–143.24071575
   PubMedGoogle Scholar
• Lee DY, Teng A, Pedersen RC, et al. Racial and socioeconomic treatment disparities in adolescents and young adults with stage II-III rectal cancer. Ann Surg Oncol. 2017;24:311–318. doi:10.1245/s10434-016-5626-027766558
   PubMed Web of Science ®Google Scholar